Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Multiple Sclerosis

  Free Subscription


26.09.2022

2 Acta Neurol Scand
1 Acta Neuropathol
1 Eur Neurol
3 J Neurol
1 J Neurol Sci
6 Mult Scler
1 Nat Rev Neurol
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neurol Scand

  1. MONTANES-MASIAS B, Bort-Roig J, Pascual JC, Soler J, et al
    Online psychological interventions to improve symptoms in multiple sclerosis: A systematic review: Online psychological interventions in Multiple Sclerosis.
    Acta Neurol Scand. 2022 Sep 19. doi: 10.1111/ane.13709.
    PubMed         Abstract available

  2. CUCE I, Altun Y
    Validity and reliability characteristics of the Silhouettes Fatigue Scale in measuring multiple sclerosis-related fatigue in Turkish-speaking adults.
    Acta Neurol Scand. 2022 Sep 19. doi: 10.1111/ane.13708.
    PubMed         Abstract available


    Acta Neuropathol

  3. TROBISCH T, Zulji A, Stevens NA, Schwarz S, et al
    Cross-regional homeostatic and reactive glial signatures in multiple sclerosis.
    Acta Neuropathol. 2022 Sep 16. pii: 10.1007/s00401-022-02497.
    PubMed         Abstract available


    Eur Neurol

  4. TATU L, Bogousslavsky J
    Treatments in Neurology: The Winding Road from 1897 to 2022.
    Eur Neurol. 2022;85:367-370.
    PubMed         Abstract available


    J Neurol

  5. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
    PubMed        

  6. FILSER M, Buchner A, Fink GR, Gold SM, et al
    The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
    J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
    PubMed         Abstract available

  7. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
    Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
    PubMed         Abstract available


    J Neurol Sci

  8. MAHLER JV, Silva GD
    Letter to the editor: Should we stop using post-contrast sequences in the follow-up MRI of patients with multiple sclerosis?
    J Neurol Sci. 2022;442:120421.
    PubMed        


    Mult Scler

  9. BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
    Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
    Mult Scler. 2022;28:1983-1996.
    PubMed         Abstract available

  10. CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
    Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
    Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
    PubMed         Abstract available

  11. GAETANI L, Schoonheim MM
    Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
    Mult Scler. 2022;28:1831-1833.
    PubMed        

  12. COHEN JA, Lublin FD, Lock C, Pelletier D, et al
    Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
    Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
    PubMed         Abstract available

  13. KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
    Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
    Mult Scler. 2022;28:1973-1982.
    PubMed         Abstract available

  14. ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
    Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Mult Scler. 2022;28:1927-1936.
    PubMed         Abstract available


    Nat Rev Neurol

  15. WILLIAMS T, Chataway J
    Beyond ocrelizumab in primary progressive multiple sclerosis.
    Nat Rev Neurol. 2022 Sep 22. pii: 10.1038/s41582-022-00724.
    PubMed        


    PLoS One

  16. ABUAF AF, Bunting SR, Klein S, Carroll T, et al
    Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches.
    PLoS One. 2022;17:e0274778.
    PubMed         Abstract available

  17. KUENDIG S, Kool J, Polhemus A, Schallert W, et al
    Three weeks of rehabilitation improves walking capacity but not daily physical activity in patients with multiple sclerosis with moderate to severe walking disability.
    PLoS One. 2022;17:e0274348.
    PubMed         Abstract available

  18. NING L, Wang B
    Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0274565.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: